Buscar
-
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
(American Journal of Hematology, 2024-02-25)Article de revueLibre acceso -
Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs.
(Haematologica, 2024-02-08)Article de revueLibre acceso -
Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms.
(Cancers. vol. 12, n° 9, 2020-08-28)Article de revueLibre acceso -
The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation
(Cancers. vol. 11, n° 12, 2019-12)Article de revueLibre acceso -
Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of NK cells is associated with the response at 6 months.
(British Journal of Haematology, 2023-04-20)Article de revueLibre acceso -
Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms.
(Journal of Thrombosis and Haemostasis, 2023-09-09)Article de revue -
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression
(British Journal of Haematology. vol. 188, n° 6, pp. 935–944, 2020)Article de revue -
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study
(American Journal of Hematology. vol. 93, n° 4, pp. E84–E86, 2018-08)Article de revueAcceso reservado -
Quantification of the Mutant CALR Allelic Burden by Digital PCR
(The Journal of Molecular Diagnostics. vol. 18, n° 1, pp. 68–74, 2016-01)Article de revue -
Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in -ITD Acute Myeloid Leukemia.
(Clinical Cancer Research, 2021-08-16)Article de revue